The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Long-Chain ω-3 Fatty Acids for Indicated Prevention of Psychotic Disorders: A Randomized, Placebo-Controlled Trial
Open accessAbstract
CONTEXT: The use of antipsychotic medication for the prevention of psychotic disorders is controversial. Long-chain omega-3 (omega-3) polyunsaturated fatty acids (PUFAs) may be beneficial in a range of psychiatric conditions, including schizophrenia. Given that omega-3 PUFAs are generally beneficial to health and without clinically relevant adverse effects, their preventive use in psychosis merits investigation. OBJECTIVE: To determine whether omega-3 PUFAs reduce the rate of progression to first-episode psychotic disorder in adolescents and young adults aged 13 to 25 years with subthreshold psychosis. DESIGN: Randomized, double-blind, placebo-controlled trial conducted between 2004 and 2007. SETTING: Psychosis detection unit of a large public hospital in Vienna, Austria. PARTICIPANTS: Eighty-one individuals at ultra-high risk of psychotic disorder. INTERVENTIONS: A 12-week intervention period of 1.2-g/d omega-3 PUFA or placebo was followed by a 40-week monitoring period; the total study period was 12 months. MAIN OUTCOME MEASURES: The primary outcome measure was transition to psychotic disorder. Secondary outcomes included symptomatic and functional changes. The ratio of omega-6 to omega-3 fatty acids in erythrocytes was used to index pretreatment vs posttreatment fatty acid composition. RESULTS: Seventy-six of 81 participants (93.8%) completed the intervention. By study's end (12 months), 2 of 41 individuals (4.9%) in the omega-3 group and 11 of 40 (27.5%) in the placebo group had transitioned to psychotic disorder (P = .007). The difference between the groups in the cumulative risk of progression to full-threshold psychosis was 22.6% (95% confidence interval, 4.8-40.4). omega-3 Polyunsaturated fatty acids also significantly reduced positive symptoms (P = .01), negative symptoms (P = .02), and general symptoms (P = .01) and improved functioning (P = .002) compared with placebo. The incidence of adverse effects did not differ between the treatment groups. CONCLUSIONS: Long-chain omega-3 PUFAs reduce the risk of progression to psychotic disorder and may offer a safe and efficacious strategy for indicated prevention in young people with subthreshold psychotic states. Trial Registration clinicaltrials.gov Identifier: NCT00396643.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Only two studies had an overall low risk of bias 33,79 ; five had unclear risk [72][73][74][75][76] , and nine had high risk 30,31,36,37,39,41,77,78,81 .”
From Lack of evidence to favor specific preventive interventions in psychosis: a network meta‐analysis (2018) · cites this paper as [33]
In the citing paper
“Earlier studies that dominated the conclusions of some previous meta-analyses (e.g., the omega-3 trial 33 ) were likely false positives.”
From Lack of evidence to favor specific preventive interventions in psychosis: a network meta‐analysis (2018) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2022) · doi:10.1176/appi.books.9780890425787 · Cited by 23,476
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
van Os, J., Linscott, R. J., Myin-Germeys, I., Delespaul, P., & Krabbendam, L. (2009) · Psychological Medicine · doi:10.1017/s0033291708003814 · Cited by 2,343
Fish Intake, Contaminants, and Human Health: Evaluating the Risks and the Benefits
Mozaffarian, D., & Rimm, E. B. (2006) · JAMA · doi:10.1001/jama.296.15.1885 · Cited by 1,966
The Family History Method Using Diagnostic Criteria
Andreasen, N. C. (1977) · Archives of General Psychiatry · doi:10.1001/archpsyc.1977.01770220111013 · Cited by 1,903
The number needed to treat: a clinically useful measure of treatment effect
Cook, R. J., & Sackett, D. L. (1995) · BMJ · doi:10.1136/bmj.310.6977.452 · Cited by 1,885
Lingjærde, O., Ahlfors, U. G., Bech, P., Dencker, S. J., & Elgen, K. (1987) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1987.tb10566.x · Cited by 1,705
Association Between Duration of Untreated Psychosis and Outcome in Cohorts of First-Episode Patients
Marshall, M., Lewis, S. W., Lockwood, A., Drake, R., Jones, P. B., & Croudace, T. J. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.9.975 · Cited by 1,595
Research works printed but not linked: 1
- First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. New York, NY: Biometrics Research, New York State Psychiatric Institute; 2002.
Cited by
Sorted by citations
Items 201–300 of 895
Amminger, G. P., Chanen, A. M., Ohmann, S., Klier, C. M., Mossaheb, N., Bechdolf, A., Nelson, B., Thompson, A. D., McGorry, P. D., Yung, A. R., et al. (2013) · The Canadian Journal of Psychiatry · doi:10.1177/070674371305800705 · Cited by 68
Self-citationNutritional interventions for the adjunctive treatment of schizophrenia: a brief review
Arroll, M. A., Wilder, L., & James, N. (2014) · Nutrition Journal · doi:10.1186/1475-2891-13-91 · Cited by 70
Messamore, E., Almeida, D. M., Jandacek, R. J., & McNamara, R. K. (2017) · Progress in Lipid Research · doi:10.1016/j.plipres.2017.01.001 · Cited by 71
New Targets for Prevention of Schizophrenia: Is It Time for Interventions in the Premorbid Phase?
Seidman, L. J., & Nordentoft, M. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv050 · Cited by 65
Kirkpatrick, B. W., Miller, B. J., García‐Rizo, C., & Fernández-Egea, E. (2013) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.kimi.031513 · Cited by 74
Prevention of Mental Disorders, Substance Abuse, and Problem Behaviors: A Developmental Perspective
Beardslee, W. R., Chien, P. L., & Bell, C. C. (2011) · Psychiatric Services · doi:10.1176/ps.62.3.pss6203_0247 · Cited by 75
Oliver, D., Raduà, J., Reichenberg, A., Uher, R., & Fusar‐Poli, P. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00174 · Cited by 69
Berger, G. E., Wood, S. J., Ross, M., Hamer, C., Wellard, R. M., Pell, G. S., Phillips, L., Nelson, B., Amminger, G. P., Yung, A. R., et al. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212799316163 · Cited by 67
Self-citationCognition dopamine and bioactive lipids in schizophrenia
Yao, J. K. (2010) · Frontiers in Bioscience-Scholar · doi:10.2741/s153 · Cited by 67
Fristad, M. A., Young, A. S., Vesco, A. T., Nader, E. S., Healy, K. Z., Gardner, W. P., Wolfson, H. L., & Arnold, L. E. (2015) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2015.0132 · Cited by 73
Diffusion Imaging of White Matter in Schizophrenia: Progress and Future Directions
Karlsgodt, K. H. (2015) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2015.12.001 · Cited by 71
Heurich, M., Föcking, M., Mongan, D., Cagney, G., & Cotter, D. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01197-9 · Cited by 68
Inflammation Theories in Psychotic Disorders: A Critical Review
Suvisaari, J., & Mantere, O. (2013) · Infectious Disorders - Drug Targets · doi:10.2174/18715265112129990032 · Cited by 68
Markulev, C., McGorry, P. D., Nelson, B., Yuen, H. P., Schaefer, M. R., Yung, A. R., Thompson, A. D., Berger, G. E., Mossaheb, N., Schlögelhofer, M., et al. (2015) · Early Intervention in Psychiatry · doi:10.1111/eip.12260 · Cited by 68
Self-citationBechdolf, A., Müller, H., Stützer, H., Wagner, M., Maier, W., Lautenschlager, M., Heinz, A., de Millas, W., Janssen, B., Gäebel, W., et al. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr083 · Cited by 66
Prodromal psychosis screening in adolescent psychiatry clinics
Loewy, R., Therman, S., Manninen, M., Huttunen, M., & Cannon, T. D. (2012) · Early Intervention in Psychiatry · doi:10.1111/j.1751-7893.2011.00286.x · Cited by 69
Amminger, G. P., Nelson, B., Markulev, C., Yuen, H. P., Schäfer, M. R., Berger, M., Mossaheb, N., Schlögelhofer, M., Smesny, S., Hickie, I. B., et al. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.08.030 · Cited by 67
Self-citationAllott, K., Schäfer, M. R., Thompson, A. D., Nelson, B., Bendall, S., Bartholomeusz, C. F., Yuen, H. P., McGorry, P. D., Schlögelhofer, M., Bechdolf, A., et al. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.01.037 · Cited by 65
Self-citationClinical high risk for psychosis in children and adolescents: a systematic review
Tor, J., Dolz, M., Sintes, A., Muñoz, D., Pardo, M., de la Serna, E., Puig, O., Sugranyes, G., & Baeza, I. (2017) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-017-1046-3 · Cited by 65
Inflammatory biomarkers in individuals at clinical high risk for psychosis (CHR-P): State or trait?
Khoury, R., & Nasrallah, H. A. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.04.017 · Cited by 65
Chen, A. T., Chibnall, J. T., & Nasrallah, H. A. (2015) · Annals of Clinical Psychiatry · doi:10.1177/104012371502700408 · Cited by 64
Clinical Staging in Psychiatry
Berger, G. (2019) · Cambridge University Press eBooks · doi:10.1017/9781139839518 · Cited by 65
Self-citationLipid Peroxidation in Psychiatric Illness: Overview of Clinical Evidence
Joshi, Y. B., & Praticò, D. (2014) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2014/828702 · Cited by 63
Walker, A. J., Kim, Y., Price, J. B., Kale, R. P., McGillivray, J., Berk, M., & Tye, S. J. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00034 · Cited by 68
Stain, H., Bucci, S., Baker, A. L., Carr, V., Emsley, R., Halpin, S., Lewin, T., Schall, U., Clarke, V., Crittenden, K., et al. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.08.008 · Cited by 62
Donovan, R. J., & Anwar‐McHenry, J. (2014) · American Journal of Lifestyle Medicine · doi:10.1177/1559827614536846 · Cited by 69
Neuroglialpharmacology: white matter pathophysiologies and psychiatric treatments
Bartzokis, G. (2011) · Frontiers in bioscience · doi:10.2741/3881 · Cited by 60
‘A Rose Is a Rose Is a Rose’, but At-Risk Criteria Differ
Schultze‐Lutter, F., SCHIMMELMANN, B. G., Ruhrmann, S., & Michel, C. (2012) · Psychopathology · doi:10.1159/000339208 · Cited by 60
Glycine treatment of the risk syndrome for psychosis: Report of two pilot studies
Woods, S. W., Walsh, B. C., Hawkins, K. A., Miller, T. J., Saksa, J. R., D’Souza, D. C., Pearlson, G. D., Javitt, D. C., McGlashan, T. H., & Krystal, J. H. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.09.008 · Cited by 61
Psychotic Disorders in Children and Adolescents: A Primer on Contemporary Evaluation and Management
Stevens, J. R., Prince, J. B., Prager, L. M., & Stern, T. A. (2014) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.13f01514 · Cited by 64
Möller, M., Swanepoel, T., & Harvey, B. H. (2015) · ACS Chemical Neuroscience · doi:10.1021/cn5003368 · Cited by 60
Hamazaki, K., Maekawa, M., Toyota, T., Dean, B., Hamazaki, T., & Yoshikawa, T. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.01.004 · Cited by 62
Raballo, A., Poletti, M., Preti, A., & McGorry, P. D. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.03.063 · Cited by 57
Self-citationClark, S. R., Baune, B. T., Schubert, K. O., Lavoie, S., Smesny, S., Rice, S., Schäfer, M. R., Benninger, F., Feucht, M., Klier, C. M., et al. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.170 · Cited by 58
Self-citationYoung people at ultra high risk for psychosis: a research update
Yung, A. R., & Nelson, B. (2011) · Early Intervention in Psychiatry · doi:10.1111/j.1751-7893.2010.00241.x · Cited by 56
Fraguas, D., González-Pinto, A. M., Micó, J. A., Reig, S., Parellada, M., Martínez‐Cengotitabengoa, M., Castro‐Fornieles, J., Rapado‐Castro, M., Baeza, I., Janssen, J., et al. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.01.040 · Cited by 57
Assessment of Pharmacotherapy for Negative Symptoms of Schizophrenia
Hanson, E., Healey, K. M., Wolf, D. H., & Kohler, C. G. (2010) · Current Psychiatry Reports · doi:10.1007/s11920-010-0148-0 · Cited by 61
Adjunct Treatments for Schizophrenia and Bipolar Disorder: What to Try When You Are Out of Ideas
Torrey, E. F., & Davis, J. M. (2011) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.5.4.5 · Cited by 56
Messamore, E., & McNamara, R. K. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0196-5 · Cited by 63
Nelson, B., Yuen, H. P., Lin, A., Wood, S. J., Mcgorry, P., Hartmann, J., & Yung, A. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.04.040 · Cited by 60
Self-citationJordan, W., Dobrowolny, H., Bahn, S., Bernstein, H., Brigadski, T., Frodl, T., Isermann, B., Leßmann, V., Pilz, J., Rodenbeck, A., et al. (2016) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-016-0749-7 · Cited by 59
Contribution of ceramides metabolism in psychiatric disorders
Bernal‐Vega, S., García‐Juárez, M., & Camacho‐Morales, A. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15759 · Cited by 57
Ghosh, S., Dyer, R., & Beasley, C. L. (2017) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2017.08.009 · Cited by 60
de Pablo, G. S., Besana, F., Arienti, V., Catalán, A., Vaquerizo‐Serrano, J., Cabras, A., Pereira, J. F., Soardo, L., Coronelli, F., Kaur, S., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.100909 · Cited by 57
Progression from being at-risk to psychosis: next steps
Addington, J., Farris, M. S., Devoe, D. J. A., & Metzak, P. D. (2020) · Schizophrenia · doi:10.1038/s41537-020-00117-0 · Cited by 59
Goh, K. K., Chen, C. Y.-A., Chen, C.-H., & Lu, M. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120981392 · Cited by 55
Mansur, R. B., Zugman, A., Asevedo, E. D. M., da Cunha, G. R., Bressan, R. A., & Brietzke, E. M. (2012) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2012.02354.x · Cited by 55
Amminger, G. P., Mechelli, A., Rice, S., Kim, S.-W., Klier, C. M., McNamara, R. K., Berk, M., McGorry, P. D., & Schäfer, M. R. (2015) · Translational Psychiatry · doi:10.1038/tp.2014.134 · Cited by 57
Self-citationChan, V. (2017) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2016.12.014 · Cited by 68
Nelson, B., Amminger, G. P., Yuen, H. P., Markulev, C., Lavoie, S., Schäfer, M. R., Hartmann, J., Mossaheb, N., Schlögelhofer, M., Smesny, S., et al. (2018) · Schizophrenia · doi:10.1038/s41537-018-0052-x · Cited by 55
Self-citationOnaolapo, O. J., & Onaolapo, A. Y. (2021) · World Journal of Clinical Cases · doi:10.12998/wjcc.v9.i28.8295 · Cited by 64
Cicero, A. F. G., Reggi, A., Parini, A., & Borghi, C. (2012) · Archives of Medical Science · doi:10.5114/aoms.2012.31613 · Cited by 55
Bellino, S., Bozzatello, P., Rocca, G., & Bogetto, F. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113510072 · Cited by 54
McNamara, R. K., Jandacek, R., Tso, P., Blom, T. J., Welge, J. A., Strawn, J. R., Adler, C. M., Strakowski, S. M., & DelBello, M. P. (2016) · Early Intervention in Psychiatry · doi:10.1111/eip.12282 · Cited by 50
Clifton, N. E., Morisot, N., Girardon, S., Millan, M. J., & Loiseau, F. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2845-3 · Cited by 57
Ayorech, Z., Tracy, D. K., Baumeister, D., & Giaroli, G. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.12.015 · Cited by 53
Why schizophrenia genetics needs epigenetics: a review.
Marić, N. P., & Švrakić, D. M. (2012) · PubMed · Cited by 53
Castillo-Passi, R. I., Rojo, L. E., Henríquez‐Henríquez, M., Hernán Silva, I., Maturana, A., Villar, M. J., Fuentes, M., & Gaspar, P. A. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00488 · Cited by 59
Föcking, M., Sabherwal, S., Cates, H. M., Scaife, C., Dicker, P., Hryniewiecka, M., Wynne, K. J., Rutten, B. P. F., Lewis, G., Cannon, M. D., et al. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0306-z · Cited by 56
Frontale Hirnvolumenminderung durch Antipsychotika?
Aderhold, V., Weinmann, S., Hägele, C., & Heinz, A. (2014) · Der Nervenarzt · doi:10.1007/s00115-014-4027-5 · Cited by 52
Focus on fatty acids in the neurometabolic pathophysiology of psychiatric disorders
Mocking, R. J. T., Assies, J., Ruhé, H. G., & Schene, A. H. (2018) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-018-0158-3 · Cited by 57
Gabbay, V., Freed, R. D., Alonso, C. M., Senger, S., Stadterman, J., Davison, B. A., & Klein, R. G. (2018) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.17m11596 · Cited by 57
Knöchel, C., Voß, M., Grüter, F., Alves, G. S., Matura, S., Sepanski, B., Stäblein, M., Wenzler, S., Prvulovic, D., Carvalho, A. F., et al. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150630173047 · Cited by 52
Armando, M., Girardi, P., Vicari, S., Menghini, D., Digilio, M. C., Pontillo, M., Saba, R., Mazzone, L., Lin, A. P., Klier, C. M., et al. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.04.020 · Cited by 51
Self-citationMcNamara, R. K. (2016) · Journal of Nutrition & Intermediary Metabolism · doi:10.1016/j.jnim.2016.04.004 · Cited by 54
Katsura, M., Ohmuro, N., Obara, C., Kikuchi, T., Ito, F., Miyakoshi, T., Matsuoka, H., & Matsumoto, K. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.06.013 · Cited by 49
People with schizophrenia and depression have a low omega-3 index
Parletta, N., Zarnowiecki, D. M., Cho, J., Wilson, A. L., Procter, N. G., Gordon, A. L., Bogomolova, S., O’Dea, K., Strachan, J., Ballestrin, M., et al. (2016) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2016.05.007 · Cited by 53
Cannabis use in individuals at clinical high-risk for psychosis: a comprehensive review
Farris, M. S., Shakeel, M. K., & Addington, J. (2019) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-019-01810-x · Cited by 49
Velthorst, E., Nieman, D. H., Klaassen, R. M. C., Becker, H. E., Dingemans, P. M. A. J., Linszen, D. H., & de Haan, L. (2010) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2010.01593.x · Cited by 48
Role of long-chain omega-3 fatty acids in psychiatric practice
McNamara, R. K., & Strawn, J. R. (2013) · PharmaNutrition · doi:10.1016/j.phanu.2012.10.004 · Cited by 51
Le-Niculescu, H., Case, N. J., Hulvershorn, L. A., Patel, S. D., Bowker, D., Gupta, J., Bell, R. L., Edenberg, H. J., Tsuang, M. T., Kuczenski, R. T., et al. (2011) · Translational Psychiatry · doi:10.1038/tp.2011.1 · Cited by 47
Li, Q., Leung, Y., Zhou, I. Y., Ho, L. C., Kong, W., Basil, P., Wei, R., Lam, S. Y., Zhang, X., Law, A. C. K., et al. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.126 · Cited by 48
Vijayakumar, N., Bartholomeusz, C., Whitford, T. J., Hermens, D. F., Nelson, B., Rice, S., Whittle, S., Pantelis, C., McGorry, P. D., Schäfer, M. R., et al. (2016) · BMC Psychiatry · doi:10.1186/s12888-016-0932-4 · Cited by 53
Self-citationEmbry, D. D. (2011) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2010.11.003 · Cited by 51
Matsuoka, Y., Nishi, D., Hamazaki, K., Yonemoto, N., Matsumura, K., Noguchi, H., Hashimoto, K., & Hamazaki, T. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09260 · Cited by 47
Twelve-month psychosis-predictive value of the ultra-high risk criteria in children and adolescents
Armando, M., Pontillo, M., Crescenzo, F. D., Mazzone, L., Monducci, E., Cascio, N. L., Santonastaso, O., Pucciarini, M. L., Vicari, S., SCHIMMELMANN, B. G., et al. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.10.033 · Cited by 47
Impact of cognitive therapy on internalised stigma in people with at-risk mental states
Morrison, A. P., Birchwood, M. J., Pyle, M., Flach, C., Stewart, S., Byrne, R. E., Patterson, P. H., Jones, P. B., Fowler, D. G., Gumley, A. I., et al. (2013) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.112.123703 · Cited by 47
de Pablo, G. S., Catalán, A., Vaquerizo‐Serrano, J., Pedruzo, B., Alameda, L., Sandroni, V., Armendariz, A., Rodríguez, V., Arango, C., Moreno, C., et al. (2023) · The British Journal of Psychiatry · doi:10.1192/bjp.2022.203 · Cited by 51
Cortical interneurons, immune factors and oxidative stress as early targets for schizophrenia
O’Donnell, P. (2012) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2012.08130.x · Cited by 47
Early intervention in psychosis: Insights from Korea
Kwon, J. S., Byun, M. S., Lee, T. Y., & An, S. K. (2012) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2012.02.007 · Cited by 46
Schizophrenia and the immune system: Pathophysiology, prevention, and treatment
Richard, M. D., & Brahm, N. C. (2012) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp110271 · Cited by 48
Cerebrospinal fluid biomarker candidates of schizophrenia: where do we stand?
Vasić, N., Connemann, B. J., Wolf, R. C., Tumani, H., & Brettschneider, J. (2011) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-011-0280-9 · Cited by 46
Kroken, R. A., Løberg, E., Drønen, T., Grüner, R., Hugdahl, K., Kompus, K., Skrede, S., & Johnsen, E. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00011 · Cited by 49
Glenthøj, L. B., Fagerlund, B., Randers, L., Hjorthøj, C. R., Wenneberg, C., Krakauer, K., Vosgerau, A., Gluud, C. N., Medalia, A. A., Roberts, D. L., et al. (2015) · Trials · doi:10.1186/s13063-014-0542-8 · Cited by 47
Niacin Skin Sensitivity Is Increased in Adolescents at Ultra-High Risk for Psychosis
Berger, G. E., Smesny, S., Schäfer, M. R., Milleit, B., Langbein, K., Hipler, U., Milleit, C., Klier, C. M., Schlögelhofer, M., Holub, M., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0148429 · Cited by 46
Self-citationSpray drying and encapsulation of omega-3 oils
Barrow, C. J., Wang, B., Adhikari, B., & Liu, H. (2013) · Elsevier eBooks · doi:10.1533/9780857098863.2.194 · Cited by 45
Update on Omega-3 Polyunsaturated Fatty Acids in Early-Stage Psychotic Disorders
Amminger, G. P., & McGorry, P. D. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.187 · Cited by 45
Self-citationPawełczyk, T., Grancow-Grabka, M., Kotlicka‐Antczak, M., Trafalska, E., Gębski, P., Szemraj, J., Żurner, N., & Pawełczyk, A. M. (2015) · BMC Psychiatry · doi:10.1186/s12888-015-0473-2 · Cited by 45
Föcking, M., Dicker, P., Lopez, L. M., Cannon, M. D., Schäfer, M. R., McGorry, P. D., Smesny, S., Cotter, D., & Amminger, G. P. (2016) · BMC Psychiatry · doi:10.1186/s12888-016-1039-7 · Cited by 46
Self-citationMcNamara, R. K., Rider, T., Jandacek, R. J., & Tso, P. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2013.12.022 · Cited by 47
Psychotherapy for adolescents and young adults at high risk for psychosis: a systematic review
Okuzawa, N., Kline, E. R., Fuertes, J., Negi, S., Reeves, G. M., Himelhoch, S. S., & Schiffman, J. E. (2014) · Early Intervention in Psychiatry · doi:10.1111/eip.12129 · Cited by 44
The Psychopharmacology Algorithm Project at the Harvard South Shore Program
Osser, D. N., Roudsari, M. J., & Manschreck, T. C. (2013) · Harvard Review of Psychiatry · doi:10.1097/hrp.0b013e31827fd915 · Cited by 45
Developmental mechanisms in the prodrome to psychosis
Walker, E. F., Trotman, H. D., Goulding, S. M., Holtzman, C. W., Ryan, A. T., McDonald, A., Shapiro, D. I., & Brasfield, J. L. (2013) · Development and Psychopathology · doi:10.1017/s0954579413000783 · Cited by 46
Gray Matter Volumetric Abnormalities Associated with the Onset of Psychosis
Jung, W. H., Borgwardt, S., Fusar‐Poli, P., & Kwon, J. S. (2012) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2012.00101 · Cited by 43
Early psychosis research at Orygen, The National Centre of Excellence in Youth Mental Health
Cotton, S., Filia, K., Ratheesh, A., Pennell, K., Goldstone, S. D., & McGorry, P. D. (2015) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-015-1140-0 · Cited by 47
Self-citationMarini, S., Berardis, D. D., Vellante, F., Santacroce, R., Orsolini, L., Valchera, A., Girinelli, G., Carano, A., Fornaro, M., Gambi, F., et al. (2016) · Mediators of Inflammation · doi:10.1155/2016/3476240 · Cited by 48
McGorry, P. D., Mei, C., Hartmann, J., Yung, A. R., & Nelson, B. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2020.12.026 · Cited by 49
Self-citationWorthington, M., & Cannon, T. D. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.770774 · Cited by 47
Rice, S., Schäfer, M. R., Klier, C. M., Mossaheb, N., Vijayakumar, N., & Amminger, G. P. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.04.036 · Cited by 43
Self-citationDeas, G., Kelly, C. J., Hadjinicolaou, A. V., Holt, C., Agius, M. A., & Zaman, R. (2016) · PubMed · Cited by 44
Metadata
- Authors
- Amminger, G. P., Schäfer, M. R., Papageorgiou, K., Klier, C. M., Cotton, S. M., Harrigan, S. M., Mackinnon, A., McGorry, P. D., & Berger, G. E.
- Affiliations
- Medical University of Vienna (AT)
- The University of Melbourne (AU)
- Clienia AG (CH)
- ORCID
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2010-02-01
- Volume
- 67
- Issue
- 2
- Pages
- 146
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2130372506
- Cited by
- 896
- References
- 45
- Citations by year
- 2026: 13 · 2025: 20 · 2024: 29 · 2023: 22 · 2022: 20 · 2021: 51 · 2020: 42 · 2019: 59 · 2018: 33 · 2017: 52 · 2016: 69 · 2015: 82 · 2014: 95 · 2013: 85 · 2012: 98
- FWCI
- 92.57
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Archives of General Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Stanley Medical Research Institute (03T-315)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- omega-3 polyunsaturated fatty acids, clinical high risk for psychosis, schizophrenia, adolescents and young adults, n-6/n-3 ratio, erythrocyte fatty acids, positive symptoms, negative symptoms, functional outcome, dietary supplementation, psychosis prevention, omega-3 deficiency
- MeSH terms
- Adolescent, Adult, Dose-Response Relationship, Drug, Double-Blind Method, Female, Health Status, Humans, Male, Patient Acceptance of Health Care, Psychotic Disorders, Risk Factors, Schizotypal Personality Disorder, Severity of Illness Index, Fatty Acids, Omega-3, Treatment Outcome, Diagnostic and Statistical Manual of Mental Disorders, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
